Tag: Artivion

Artivion Publishes Inaugural Corporate Responsibility Report

ATLANTA, March 14, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Report detailing the company’s Environmental, Social, and Governance (ESG) initiatives. Artivion’s 2022 Corporate Responsibility Report details several of the company’s ESG efforts, including: Environmental initiatives to drive sustainability and limit […]

Artivion Reports Fourth Quarter and Full Year 2021 Financial Results

ATLANTA, Feb. 17, 2022 /PRNewswire/ — Fourth Quarter and Recent Business Highlights: Achieved record revenue of $79.4 million in the fourth quarter 2021 versus $67.9 million in the fourth quarter of 2020, an increase of 16.9% on a GAAP basis and 18.8 % on a non-GAAP proforma constant currency basis Received FDA approval to launch enrollment […]

Artivion Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in The Annals of Thoracic Surgery

Results Presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons ATLANTA, Jan. 31, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society […]

CryoLife Announces Corporate Rebranding and Changes Name to Artivion

Artivion to Host Investor & Analyst Day on March 23, 2022 ATLANTA, Jan. 18, 2022 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words “aorta”, “innovation”, and […]